| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6251910 | ASTRAZENECA | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
Jul, 2018
(5 years ago) | |
| US6525060 | ASTRAZENECA | Triazolo(4,5-d)pyrimidine compounds |
Dec, 2019
(4 years ago) | |
| US7250419 | ASTRAZENECA | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Dec, 2019
(4 years ago) | |
| US7265124 | ASTRAZENECA | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
Jul, 2021
(2 years ago) | |
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE46276 (Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(1 year, 3 days from now) | |
| US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(5 years from now) | |
|
US8425934 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
| US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(11 years from now) | |
|
US10300065 (Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(12 years from now) | |
Brilinta is owned by Astrazeneca.
Brilinta contains Ticagrelor.
Brilinta has a total of 10 drug patents out of which 4 drug patents have expired.
Expired drug patents of Brilinta are:
- US6251910
- US6525060
- US7250419
- US7265124
Brilinta was authorised for market use on 03 September, 2015.
Brilinta is available in tablet;oral dosage forms.
Brilinta can be used as method of inhibiting platelet aggregation, reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily, reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, treatment of post-myocardial infarction, reduction of the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.
Drug patent challenges can be filed against Brilinta from 09 November, 2024.
The generics of Brilinta are possible to be released after 27 July, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
| New Indication(I-851) | May 28, 2023 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-714) | Sep 03, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagre...
Dosage: TABLET;ORAL
BRILINTA family patents
